The challenge in controlling BRD is to identify and quantify the factors that account for the immunosuppression. This is easier said than done, since knowledge of biomarkers for quantification of stress is incomplete and chuteside implementation is not yet possible.

Many useful pharmaceutical products have been developed to treat BRD; however, effective implementation of a preventive strategy has been elusive. A further complication is the absence of an experimental model that replicates the most common clinical symptoms.